In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
As of close of business last night, Strata Critical Medical Inc’s stock clocked out at $4.2, up 4.22% from its previous closing price of $4.03. In other words, the price has increased by $4.22 from its previous closing price. On the day, 1.27 million shares were traded. SRTA stock price reached its highest trading level at $4.29 during the session, while it also had its lowest trading level at $4.0.
Ratios:
To gain a deeper understanding of SRTA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.39 and its Current Ratio is at 4.39. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In the most recent recommendation for this company, Lake Street on February 26, 2025, initiated with a Buy rating and assigned the stock a target price of $6.50.
On July 18, 2023, Ladenburg Thalmann started tracking the stock assigning a Buy rating and target price of $13.
On July 17, 2023, Ladenburg Thalmann started tracking the stock assigning a Buy rating and target price of $13.Ladenburg Thalmann initiated its Buy rating on July 17, 2023, with a $13 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 19 ’25 when Love Reginald sold 11,000 shares for $4.31 per share. The transaction valued at 47,434 led to the insider holds 124,897 shares of the business.
Reginald Lamonte Love bought 11,000 shares of SRTA for $48,070 on Nov 20 ’25. On Nov 19 ’25, another insider, Reginald Lamonte Love, who serves as the Director of the company, bought 11,000 shares for $4.31 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SRTA now has a Market Capitalization of 362739392 and an Enterprise Value of 15956216. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.59 while its Price-to-Book (P/B) ratio in mrq is 1.28. Its current Enterprise Value per Revenue stands at 0.238 whereas that against EBITDA is -0.518.
Stock Price History:
The Beta on a monthly basis for SRTA is 2.02, which has changed by 0.12299466 over the last 52 weeks, in comparison to a change of 0.1028198 over the same period for the S&P500. Over the past 52 weeks, SRTA has reached a high of $6.02, while it has fallen to a 52-week low of $2.35. The 50-Day Moving Average of the stock is -15.89%, while the 200-Day Moving Average is calculated to be 6.49%.
Shares Statistics:
It appears that SRTA traded 858.02K shares on average per day over the past three months and 1197480 shares per day over the past ten days. A total of 86.05M shares are outstanding, with a floating share count of 60.85M. Insiders hold about 29.55% of the company’s shares, while institutions hold 52.81% stake in the company. Shares short for SRTA as of 1761868800 were 2599765 with a Short Ratio of 3.03, compared to 1759190400 on 2138637. Therefore, it implies a Short% of Shares Outstanding of 2599765 and a Short% of Float of 4.4899996.
Earnings Estimates
The company has 1.0 analysts who recommend its stock at the moment.
Analysts are recommending an EPS of between -$0.15 and -$0.15 for the fiscal current year, implying an average EPS of -$0.15. EPS for the following year is $0.08, with 1.0 analysts recommending between $0.08 and $0.08.
Revenue Estimates
In. The current quarter, 1 analysts expect revenue to total $60M. It ranges from a high estimate of $60M to a low estimate of $60M. As of. The current estimate, Strata Critical Medical Inc’s year-ago sales were $54.36M
A total of 1 analysts have provided revenue estimates for SRTA’s current fiscal year. The highest revenue estimate was $190.35M, while the lowest revenue estimate was $190.35M, resulting in an average revenue estimate of $190.35M. In the same quarter a year ago, actual revenue was $248.69MBased on 1 analysts’ estimates, the company’s revenue will be $270M in the next fiscal year. The high estimate is $270M and the low estimate is $270M.
